Experts discuss the goals of treatment of patients with Dravet syndrome regarding seizure freedom and seizure burden.
Videos
The acute care nurse practitioner at Overlook Medical Center discussed the presentation she gave at the Atlantic Health Stroke Symposium on the care of the hemorrhagic stroke in the neuro-ICU setting.
Experts discuss different strategies to manage concerns relating to advanced Parkinson disease including patient education.
A discussion about how to educate and speak with patients with advanced Parkinson disease.
Elaine Wirrell, MD, reviews the transition of care into adulthood of patients with Dravet syndrome and how this transition can affect the patient, caregiver, and care provider.
The panel discusses the impact on the family, siblings, or caregivers of patients with Dravet syndrome.
The chief medical officer of Scholar Rock discussed topline results from the phase 2 TOPAZ study of apitegromab in patients with spinal muscular atrophy.
The duo from Cleveland Clinic discussed their presentation from AHS 2021 regarding the effects of COVID-19 on access to telemedicine visits among minorities.
Neurology News Network for the week ending July 2, 2021.
The pediatric headache specialist at NYU Langone discussed the lifestyle choices children and parents must make to ensure optimal management of pediatric migraine.
Clive Ballard, MD, discussed up-and-coming technologies for remote risk assessment, among other data presented at this year’s AAIC meeting.
Experts in multiple sclerosis (MS) provide an overview of treatment strategies and selection in relapsing MS.
Considerations of genetic testing regarding family planning as well as behavioral issues associated with Dravet syndrome.
Fred D. Lublin, MD discusses the diagnosis of multiple sclerosis and the 2017 revisions of the McDonald criteria.
The clinical fellow at Massachusetts General Hospital discussed his approach to highlighting flaws within the medical education system and the need to do so for certain areas in epilepsy.
Elaine C. Wirrell, MD, explains the increased risk of sudden unexpected death in epilepsy (SUDEP) in patients with Dravet syndrome and how to talk about it with caregivers and families.
Michael J. Soileau, MD, discusses how to recognize when a patient has advanced Parkinson disease, what are the initial or relevant signs and symptoms of advanced disease, and how patients shift from early to intermediate and advanced disease.
John Brandsema, MD, and Julie Parsons, MD, discuss the approval of nusinersen for the treatment of spinal muscular atrophy and their personal experiences regarding drug safety and administration in patients.
Joohi Jimenez-Shahed, MD, describes the natural progression of Parkinson disease from the time of diagnosis to advanced disease.
Expert pediatric neurologists review the importance of early recognition and referral to neurologists for the diagnosis of spinal muscular atrophy and when it’s appropriate to approach treatment.
The director of the Montefiore Headache Center discussed the momentum within the migraine research community as well as some of the more notable presentations from AHS 2021.
The executive director of the LEAD Coalition calls for greater collaboration and support from government and the healthcare community in order to boost health equity.
The pediatric headache specialist at NYU Langone discussed what physicians should be aware of related to the signs and symptoms associated with pediatric migraine.
The vice president of Medical Affairs in Migraine at Impel discussed the clinical takeaways from the STOP 301 trial of intranasal DHE and the advantages that the novel formulation might offer patients with migraine.
Neurology News Network for the week ending June 26, 2021.
Elaine Wirrell, MD, provides background on fenfluramine, results from 2 clinical trials, and compares it to other treatment therapies.
Elizabeth Thiele, MD, PhD, reviews cannabidiol oral solution as treatment of seizures associated with Dravet syndrome and the safety profile and dosing associated with it.
The professor of Molecular Neuroscience at the Edmond and Lily Safra Center for Brain Sciences provided thoughts on the comfortability of prescribing aducanumab knowing its safety profile.
The clinical fellow at Massachusetts General Hospital discussed the basis of his study evaluating adult neurology trainees and their familiarity with SUDEP and its risks.
The vice president of Medical Affairs in Migraine at Impel discussed the STOP 301 trial of intranasal DHE and how the safety profile offers a positive for patients who would use the agent on-demand.
Advertisement
Advertisement
